

Male and Female				Male				Female			
Cancer Site	U.S. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)
All Sites	433.2	454.9 ▲	3,656	All Sites	473.5	479.2	1,818	All Sites	406.2	439.8 ▲	1,838
Lung and Bronchus	58.2	63.3 ▲	522	Prostate	107.4	92.0 ▼	383	Breast	123.9	130.4 ▲	540
Colon and Rectum	38.6	36.1 ▼	289	Lung and Bronchus	68.2	69.9	266	Lung and Bronchus	50.6	58.3 ▲	256
Melanoma of the Skin	21.2	33.1 ▲	261	Melanoma of the Skin	27.2	41.4 ▲	154	Uterus	26.1	33.5 ▲	148
Urinary Bladder	20.1	22.8 ▲	186	Colon and Rectum	44.4	38.7 ▼	144	Colon and Rectum	33.8	33.4	145
Non-Hodgkin Lymphoma	18.6	22.0 ▲	173	Urinary Bladder	35.1	37.6	138	Melanoma of the Skin	16.8	26.8 ▲	107
Thyroid	14.4	13.7	92	Non-Hodgkin Lymphoma	22.5	26.2 ▲	96	Thyroid	21.4	19.7	66
Kidney	16.1	13.6 ▼	108	Kidney	21.8	19.0 ▼	71	Non-Hodgkin Lymphoma	15.5	18.4 ▲	78
Leukemia	13.3	12.8	98	Oral Cavity/Throat	17.4	17.2	69	Ovary	11.1	11.7	48
Pancreas	12.0	12.2	99	Leukemia	16.9	16.2	57	Urinary Bladder	8.6	10.7 ▲	48
Oral Cavity/Throat	11.5	11.6	97	Pancreas	13.7	14.5	54	Pancreas	10.6	10.3	45
Brain/Nervous System	6.3	6.7	50	Esophagus	7.7	10.0 ▲	40	Leukemia	10.3	10.0	41
Esophagus	4.5	6.0 ▲	50	Liver	11.7	8.4 ▼	35	Kidney	11.3	8.9 ▼	37
Myeloma	6.4	5.6	46	Myeloma	8.0	7.8	28	Oral Cavity/Throat	6.3	6.6	28
Liver	7.6	5.2 ▼	45	Brain/Nervous System	7.4	7.8	28	Brain/Nervous System	5.4	5.7	22
Stomach	6.5	4.7 ▼	38	Thyroid	7.2	7.6	27	Cervix	7.5	4.4 ▼	14
Larynx	3.3	3.8	31	Stomach	8.9	7.0 ▼	26	Myeloma	5.2	3.8 ▼	17
Hodgkin Lymphoma	2.6	3.1	20	Larynx	5.7	6.4	25	Hodgkin Lymphoma	2.3	2.9	9
				Testis	5.6	6.3	19	Stomach	4.5	2.7 ▼	12
				Hodgkin Lymphoma	3.0	3.4	11	Esophagus	1.7	2.5	11
								Liver	4.1	2.3 ▼	10
								Larynx	1.3	1.5	6

▲ Statistically higher than the U.S. rate.

▼ Statistically lower than the U.S. rate.

TECHNICAL NOTES: All rates are age adjusted to the 2000 U.S. standard population and exclude basal cell and squamous cell skin cancers. Incidence rates exclude in situ carcinomas except urinary bladder. Incidence data were coded using the International Classification of Disease for Oncology (ICD-O) coding system. Vermont cases include Vermont residents only. The Vermont and U.S. incidence rates are based on the Vermont Cancer Registry, Vermont Department of Health (1994-2015) and the NPCR and SEER Incidence - U.S. Cancer Statistics Public Use Database, Nov 2017 submission (2001-2015). A reporting delay by Department of Veterans Affairs (VA) has resulted in incomplete reporting of VA hospital cases in 2011-2014.

COPYRIGHT INFORMATION: All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

SUGGESTED CITATION: Age Adjusted Cancer Incidence Rates, 2011-2015, Vermont Department of Health, Burlington, VT, 2018.

ACKNOWLEDGEMENT: This publication was supported by the Grant or Cooperative Agreement Number, NU58DP006322, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

Male and Female				Male				Female			
Cancer Site	U.S. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)
All Sites	163.5	168.6 ▲	1,363	All Sites	196.8	198.9	715	All Sites	139.6	146.1 ▲	648
Lung and Bronchus	43.4	45.2	369	Lung and Bronchus	53.8	51.9	192	Lung and Bronchus	35.4	40.1 ▲	176
Colon and Rectum	14.5	14.1	113	Prostate	19.5	20.2	67	Breast	20.9	19.2	85
Pancreas	10.9	11.1	90	Colon and Rectum	17.3	15.7	57	Colon and Rectum	12.2	12.5	57
Leukemia	6.7	6.5	51	Pancreas	12.6	12.7	47	Pancreas	9.5	9.8	43
Non-Hodgkin Lymphoma	5.7	6.0	48	Urinary Bladder	7.6	9.3 ▲	31	Ovary	7.2	7.6	33
Urinary Bladder	4.4	5.8 ▲	46	Leukemia	9.0	9.0	30	Uterus	4.6	5.4	25
Brain/Nervous System	4.4	5.6 ▲	44	Esophagus	7.2	8.7 ▲	33	Brain/Nervous System	3.6	4.7 ▲	19
Esophagus	4.0	5.0 ▲	41	Non-Hodgkin Lymphoma	7.4	8.5	29	Leukemia	5.0	4.6	21
Liver	6.4	4.4 ▼	37	Brain/Nervous System	5.3	6.7 ▲	25	Non-Hodgkin Lymphoma	4.5	4.1	19
Kidney	3.8	3.3	28	Liver	9.4	6.5 ▼	25	Urinary Bladder	2.2	3.4 ▲	15
Oral Cavity/Throat	2.5	3.1 ▲	26	Kidney	5.6	4.9	18	Liver	3.8	2.6 ▼	12
Myeloma	3.3	3.1	26	Oral Cavity/Throat	3.9	4.4	17	Myeloma	2.7	2.3	11
Stomach	3.2	2.6	21	Stomach	4.3	4.3	15	Kidney	2.4	2.0	9
Melanoma of the Skin	2.6	2.5	21	Myeloma	4.2	4.1	15	Oral Cavity/Throat	1.3	2.0 ▲	9
Larynx	1.0	1.1	9	Melanoma of the Skin	3.9	3.5	13	Esophagus	1.5	1.9	8
Thyroid	0.5	0.4	4	Larynx	1.8	1.8	7	Melanoma of the Skin	1.6	1.7	8
Hodgkin Lymphoma	0.3	0.3	2	Thyroid	0.5	0.5	2	Stomach	2.3	1.3 ▼	6
				Hodgkin Lymphoma	0.4	0.4	1	Cervix	2.3	1.0 ▼	4
				Testis	0.2	0.4	1	Larynx	0.4	0.5	2
								Thyroid	0.5	0.4	2
								Hodgkin Lymphoma	--	--	<1

▲ Statistically higher than the U.S. rate.

▼ Statistically lower than the U.S. rate.

TECHNICAL NOTES: All rates are age adjusted to the 2000 U.S. standard population and exclude basal cell and squamous cell skin cancers. Mortality data were coded using the International Classification of Disease Tenth Revision (ICD-10) coding system. Vermont deaths include Vermont residents only. -- Rates based on 5 or fewer deaths are not individually calculated. The Vermont and the U.S. mortality rates are based on the Vermont Vital Statistics System, Vermont Department of Health (1994-2015) and the SEER Program Mortality - Aggregated Total U.S. (1990-2015).

COPYRIGHT INFORMATION: All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

SUGGESTED CITATION: Age Adjusted Cancer Mortality Rates, 2011-2015, Vermont Department of Health, Burlington, VT, 2018.

ACKNOWLEDGEMENT: This publication was supported by the Grant or Cooperative Agreement Number, NU58DP006322, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.